Skip to main content

Novo Nordisk mounts unusual challenge to medicare price negotiation program

By STAT News  
   April 21, 2025

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have major ramifications for the Medicare drug price negotiation program, a signature accomplishment of former President Biden that President Trump has also embraced.

Full story


Get the latest on healthcare leadership in your inbox.